CTLT - Catalent, Inc.

Catalent specializes in providing comprehensive drug development and manufacturing solutions for a diverse range of pharmaceutical and consumer health products, including biologics, vaccines, and cell and gene therapies. Operating approximately 50 facilities across four continents, the company leverages its extensive capabilities in formulation, regulatory compliance, and clinical trial support to help clients accelerate time-to-market for their products. Notably, Catalent has played a role in facilitating the FDA approval of more than half of new drug products in the past decade, reflecting its deep industry expertise.

The company operates through two primary segments: Biologics, which focuses on cell and gene therapies, biologic drug substances, and their manufacturing processes; and Pharma and Consumer Health, which handles traditional and advanced pharmaceutical products, including softgels and various dosage forms. Catalent’s robust customer base includes 88 of the top 100 branded drug marketers and 82 of the top 100 biologics marketers worldwide, indicating significant trust and reliability in their long-standing relationships with key industry players. Catalent's strategy includes expanding its manufacturing capabilities and technology offerings to further enhance growth in the rapidly evolving biopharmaceutical market.